Completed PHASE2 INTERVENTIONAL NCT00010868

Omega-3 Fatty Acids in Bipolar Disorder

Omega-3 Fatty Acids in Bipolar Disorder Prophylaxis

Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Updated 5 times since 2017 Last updated: Aug 17, 2006 Started: Jul 31, 2000 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00010868, this PHASE2 trial focuses on Bipolar Disorder and remains completed. Sponsored by National Center for Complementary and Integrative Health (NCCIH), it has been updated 5 times since 2000, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Center for Complementary and Integrative Health (NCCIH)
Pronova BioPharma

Data source: National Center for Complementary and Integrative Health (NCCIH)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Belmont, United States
• Houston, United States